Form D · Biotechnology
Avivomed Inc.
Roseville, MN · CIK 0001893991
Offering snapshot reported Apr 21, 2026 · SEC filing
- Reported sold
- $5M Offering amount: $12M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 16, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 21, 2026 | Initial | $5,000,000 | No comparison | 7 | SEC filing |
| Nov 16, 2021 | Initial | $20,118,334 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-581292
Source: Form D, filed Apr 21, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Casper De Clercq | Director |
| Mudit K. Jain | Director |
| Stephen Masson | Director, Executive |
| Paul Mazanec | Director, Executive |
| Theresa C. Pappas | Director |
| Ketan Patel | Director |
| Douglas Reed | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2896 Centre Pointe Drive
Roseville, MN, 55113
Roseville, MN, 55113